威海廣泰(002111.SZ):簽訂3.31億元的裝備訂購合同
格隆匯10月21日丨威海廣泰(002111.SZ)公佈,近日,公司收到與軍方某部簽訂的《裝備訂購合同》,合同金額33097萬元。
上述合同金額33097萬元人民幣,佔公司2019年度經審計營業收入的12.97%,佔軍品營業收入的67.11%,合同的執行將對公司2021年經營成果產生積極的影響。
2020年,公司進一步加大對軍工業務的支持力度,從研發到採購,從生產到交付,不斷提升軍工產品的質量和性能,不斷拓展市場範圍,不斷承接新的大型軍工裝備研發項目,保障公司軍工業務的持續發展。本年度公司已累計簽訂軍品裝備合同或中標軍品採購項目金額超過10億元,為107368.7萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.